GlaxoSmithKline PLC (GSK)

GSK (NYSE:Drugs)
$46.52
pos +0.24
+0.52%
Today's Range: 46.30 - 46.57 | GSK Avg Daily Volume: 5,054,700
Last Update: 11/26/14 - 4:02 PM EST
Volume: 2,047,047
YTD Performance: -13.32%
Open: $46.44
Previous Close: $46.28
52 Week Range: $41.91 - $56.73
Oustanding Shares: 2,402,000,000
Market Cap: 111,140,540,000
6-Month Chart
TheStreet Ratings Grade for GSK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 3.00 3.00 3.00 3.00
Latest Dividend: 0.61
Latest Dividend Yield: 5.73%
Dividend Ex-Date: 11/05/14
Price Earnings Ratio: 15.90
Price Earnings Comparisons:
GSK Sector Avg. S&P 500
15.90 16.10 26.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.84% -12.38% 11.52%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.30 0.00 0.00
Net Income 21.10 2.25 0.47
EPS 23.20 2.75 0.55
Earnings for GSK:
EBITDA 11.43B
Revenue 43.71B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.87 $n.a. $3.06 $3.07
Number of Analysts 1 0 6 6
High Estimate $0.87 $n.a. $3.22 $3.40
Low Estimate $0.87 $n.a. $2.87 $2.82
Prior Year $0.95 $0.70 $3.46 $3.06
Growth Rate (Year over Year) -8.42% n.a.% -11.71% 0.44%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Merger Mania Benefits Mylan Real Money Pro($)

Whether it's acquiring or the acquired, Mylan is building shareholder value.
Americans are living much longer these days -- and there are a number of ways to invest.
Stop picking on PepsiCo, Allergan and Apple.
European stocks reach highest level since Jan. 2008.
European stocks pull back on new worries about Ukraine.
McDonald's and GlaxoSmithKline are fighting against major turns of the tide.
Your portfolio could use an English touch.
Bullish
Apr 23, 2014 | 8:24 AM EDT
GSK was upgraded from Hold to Buy, Argus said. Asset swap with Novartis is attractive. 
Futures point higher; blockbuster drug deal boosts European markets.

The Cloud Is the Prescription Real Money Pro($)

Medidata Solutions is focusing its cloud-computing offerings on the pharmaceutical industry.

Columnist Conversations

Lang:
Lights, Camera, ACTION! This move lately in GPRO has been stellar, up nearly 12% over the past couple of sess...
For just under two weeks MCD has been bumping up against a very solid wall of resistance. The $96.95 to ...
Texas Instruments is surging today. Shares are up over 2.7% and are moving further into new 52W high gro...
Shares of Amazon (AMZN) have been trading within a set of Fibonacci retracements measured off their 2014 range...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.